Low-molecular-weight heparin in the treatment of deep venous thrombosis.

  title={Low-molecular-weight heparin in the treatment of deep venous thrombosis.},
  author={Karen E. Hauer},
  journal={The Western journal of medicine},
  volume={169 4},
Traditionally, acute deep venous thrombosis (DVT) is treated with intravenous heparin followed by oral anticoagulants. With the advent of the low-molecular-weight heparins (LMWHs), this strategy is changing dramatically. LMWHs are compounds derived from standard unfractionated heparin that offer distinct clinical advantages over unfractionated heparin, including better bioavailability, longer half-life, and a more predictable anticoagulant response that obviates the need for laboratory… CONTINUE READING